BDBM21 CHEMBL24828::N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine::VANDETANIB::ZD-6474::ZD6474::cid_3081361

SMILES CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br

InChI Key InChIKey=UHTHHESEBZOYNR-UHFFFAOYSA-N

Data  7 KI  96 IC50  914 Kd

PDB links: 1 PDB ID matches this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1017 hits for monomerid = 21   

TargetGag-Pol polyprotein [489-587](Human immunodeficiency virus type 1)
TBA

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKi:  0.240nMAssay Description:Inhibitory activity against HIV-1 proteaseMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2010
Entry Details Article

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 4nMAssay Description:In order to assess the activity of chemical compounds against the relevant kinase of interest, the Caliper LifeSciences electrophoretic mobility shif...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2020
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
Ambit Biosciences

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  4.60nMAssay Description:Binding constant for RIPK2 kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
Ambit Biosciences

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  4.60nMAssay Description:Binding constant for RIPK2 kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
Ambit Biosciences

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  4.60nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  4.80nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2011
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  4.80nMAssay Description:Binding constant for EGFR(E746-A750del) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  4.80nMAssay Description:Binding constant for EGFR(E746-A750del) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  5.90nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2011
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  5.90nMAssay Description:Binding constant for EGFR(G719S) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  5.90nMAssay Description:Binding constant for EGFR(G719S) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  7.90nMAssay Description:Binding constant for EGFR(L747-S752del, P753S) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  7.90nMAssay Description:Binding constant for EGFR(L747-S752del, P753S) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  7.90nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2011
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  8.70nMAssay Description:Binding constant for EGFR(L858R) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  8.70nMAssay Description:Binding constant for EGFR(L858R) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  8.90nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2011
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  8.90nMAssay Description:Binding constant for EGFR(L747-T751del,Sins) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  8.90nMAssay Description:Binding constant for EGFR(L747-T751del,Sins) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 9nMAssay Description:Inhibition of recombinant human RET using KKKSPGEYVNIEFG as substrate incubated for 15 mins followed by Mg/ATP addition and measured after 40 mins by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/29/2022
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase ABL1(Human)
Ambit Biosciences

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9nMAssay Description:Binding constant for ABL1(Y253F)-phosphorylated kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9.5nMAssay Description:Binding affinity to wild-type human partial length EGFR (R669 to V1011 residues) expressed in bacterial expression system by Kinomescan methodMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/24/2021
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9.5nMAssay Description:Binding constant for EGFR kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9.5nMAssay Description:Binding constant for EGFR kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9.5nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2011
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor [G719C](Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9.60nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9.60nMAssay Description:Binding constant for EGFR(G719C) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9.60nMAssay Description:Binding constant for EGFR(G719C) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetTyrosine-protein kinase ABL1(Human)
Ambit Biosciences

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  9.80nMAssay Description:Binding constant for ABL1(H396P)-non phosphorylated kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  11nMAssay Description:Binding constant for EGFR(L861Q) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  11nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2011
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 11nMAssay Description:Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2018
Entry Details Article
PubMed
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  11nMpH: 7.4 T: 2°CAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/14/2009
Entry Details
PCBioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  11nMAssay Description:Binding constant for DDR1 kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  11nMAssay Description:Binding constant for EGFR(L861Q) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  11nMAssay Description:Binding constant for DDR1 kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  12nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/23/2011
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  12nMAssay Description:Binding constant for EGFR(L747-E749del, A750P) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  12nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2011
Entry Details
PCBioAssay
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  12nMAssay Description:Binding constant for EGFR(S752-I759del) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  12nMAssay Description:Binding constant for EGFR(L747-E749del, A750P) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Ambit Biosciences

Curated by PubChem BioAssay
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  12nMAssay Description:Binding constant for EGFR(S752-I759del) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMed
TargetTyrosine-protein kinase ABL1(Human)
Ambit Biosciences

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  13nMAssay Description:Binding constant for ABL1(E255K)-phosphorylated kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  14nMAssay Description:Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets. The biological consequences of multi-kinase activity...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/21/2011
Entry Details
PCBioAssayPDB3D3D Structure (crystal)
TargetTyrosine-protein kinase ABL1(Human)
Ambit Biosciences

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  14nMAssay Description:Binding constant for ABL1(H396P)-phosphorylated kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  14nMAssay Description:Binding constant for RET(M918T) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
12/25/2012
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Blueprint Medicines

US Patent
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  14nMAssay Description:Binding constant for RET(M918T) kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetVascular endothelial growth factor receptor 2(Human)
Wyeth Research

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 15nMAssay Description:Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase ABL1(Human)
Ambit Biosciences

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataKd:  15nMAssay Description:Binding constant for ABL1(M351T)-phosphorylated kinase domainMore data for this Ligand-Target Pair
In Depth
Date in BDB:
7/19/2012
Entry Details Article
PubMed
TargetVascular endothelial growth factor receptor 2(Human)
Wyeth Research

Curated by ChEMBL
LigandPNGBDBM21(VANDETANIB | N-(4-bromo-2-fluorophenyl)-6-methoxy-...)
Affinity DataIC50: 15nMAssay Description:Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2018
Entry Details Article
PubMed
Displayed 1 to 50 (of 1017 total ) | Next | Last >>